Open AccessInitial Impairment and Recovery of Vision-Related Functioning in Participants With Acute Optic Neuritis From the RENEW Trial of Opicinumab
Author(s) -
Jennifer Petrillo,
Laura J. Balcer,
Steven Galetta,
Yi Chai,
Lei Xu,
Diego Cadavid
Publication year - 2019
Publication title -
journal of neuro-ophthalmology
Language(s) - English
Resource type - Journals
eISSN - 1536-5166
pISSN - 1070-8022
DOI - 10.1097/wno.0000000000000697
Subject(s) - placebo , medicine , optic neuritis , population , randomized controlled trial , multiple sclerosis , pathology , immunology , alternative medicine , environmental health
Leucine-rich repeat and immunoglobulin domain-containing Nogo receptor-interacting protein 1 (LINGO-1) is a key suppressor of oligodendrocyte differentiation and axonal remyelination and regeneration. This analysis evaluated the potential benefit of opicinumab, a human monoclonal antibody against LINGO-1, vs placebo on exploratory clinical endpoints of patient-reported vision-related functioning and high-contrast visual acuity (HCVA) in RENEW participants with acute optic neuritis (AON).